Tirzepatide is a GIP + GLP-1 dual agonist physician prescribed for weight loss. Our program offers individualized dosing to help support weight loss and appetite reduction through two separate metabolic pathways simultaneously.
Semaglutide is a GLP-1 receptor agonist prescribed for physician supervised weight loss, with an extensive clinical record and well-established efficacy in weight management.
If prescribed, your treatment is shipped discreetly to your door. No insurance required. Compounded tirzepatide and semaglutide are not FDA-approved.
Tirzepatide is a physician prescribed GIP and GLP-1 dual receptor agonist — meaning it activates two separate metabolic pathways simultaneously. By engaging both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide produces enhanced appetite suppression and metabolic improvement compared to single-receptor GLP-1 medications. Clinical trials show up to 22% average body weight reduction — among the highest published results for any medication in this class.
Semaglutide is a physician prescribed GLP-1 receptor agonist with an extensive clinical record in the treatment of obesity and weight management. By activating the GLP-1 receptor, semaglutide reduces appetite, slows gastric emptying, and improves insulin sensitivity — supporting meaningful, sustained weight loss under physician supervision. It is one of the most studied medications in its class, with published clinical results showing up to 15% average body weight reduction.
Your physician selects the right medication based on your health history, BMI, and weight loss goals. Both programs follow the same streamlined process.
Complete a short health intake and a licensed physician will review your profile and determine whether tirzepatide or semaglutide is the most clinically appropriate option for your goals.
No upfront fee · Physician review required · Not all patients qualify · Compounded medications are not FDA-approved